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ABSTRAK
Aterosklerosis merupakan suatu proses peradangan kronik, yang melibatkan imunitas alamiah dan adaptif. 
Respon sel T efektor (Teff) berperan dalam mempercepat terjadinya aterosklerosis. Adapun sel T regulator (Treg), 
mempunyai peran sebagai komponen pelindung dalam proses aterosklerosis melalui modulasi respon inflamasi 
yang melibatkan berbagai mekanisme. Dari berbagai studi eksperimental menunjukkan bahwa perubahan 
keseimbangan antara Treg/Teff dengan polarisasi ke arah Treg dapat menjadi pendekatan terapeutik pada 
aterosklerosis, meskipun peran Treg dalam studi klinis belum sepenuhnya dapat dijelaskan. Dalam tinjauan 
pustaka ini, kami akan menelaah berbagai perkembangan dan pemahaman terkini mengenai peran Treg dan 
Teff dalam studi eksperimental dan klinis aterosklerosis.
Kata kunci: aterosklerosis, sel T regulator, peradangan.
ABSTRACT
Atherosclerosis is a chronic inflammatory disorder involving innate and adaptive immunity process. Effector 
T cell (Teff) responses promote atherosclerotic disease, whereas regulatory T cells (Tregs) have been shown to 
play a protective role against atherosclerosis by down-regulating inflammatory responses which include multiple 
mechanisms. Compelling experimental data suggest that shifting the Treg/Teff balance toward Tregs may be a 
possible therapeutic approach for atherosclerotic disease, although the role of Tregs in human atherosclerotic 
disease has not been fully elucidated. In this review, we discuss recent advances in our understanding of the 
roles of Tregs and Teffs in experimental atherosclerosis, as well as human coronary artery disease.
Keywords: atherosclerosis, regulatory T cells, inflammation.
INTRODUCTION
Atherosclerotic disease is a major cause 
of mortality worldwide. Atherosclerosis has 
been known as a chronic inflammatory disorder 
involving innate and adaptive immunity process.1 
T cell-mediated immune responses play an 
important role in atherogenesis.2 Therefore, 
specific targeted approach to inflammatory 
responses may be effective to improve 
cardiovascular outcome.
T cells, macrophages, and smooth muscle 
cells, which generate cytokines, growth 
factors, and pro-inflammatory mediators are 
found in atherosclerotic plaques. Although 
several suspected self-antigens important for 
atherosclerosis are reported, critical antigens have 
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not been identified. After antigen presentation, 
naïve T cells differentiate into effector T cells 
(Teffs), which may promote atherosclerotic 
disease. Importantly, regulatory T cell (Treg) 
expressing CD25 molecule and the transcription 
element FoxP3 (fork-head box P3) have 
been shown to play a protective role against 
atherosclerosis by down-regulating inflammatory 
responses.2 In this review, we discuss recent 
advances in our understanding of the roles of 
Tregs and Teffs in experimental atherosclerosis, 
as well as human coronary artery disease.
EFFECTOR T CELLS AND ATHEROSCLERO-
SIS PROGRESSION
After antigen presentation or activation by 
macrophages or dendritic T cell (DCs), naïve 
CD4+ T cells differentiate into Teffs such as T 
helper type 1 (Th1), T helper type 2 (Th2), and 
T helper type 17 (Th17) cells, which all critically 
affect atherogenesis in both humans and mice.3 
Th1 cells are known to promote atherosclerotic 
disease, whereas the roles of Th2 and Th17-
mediated immune responses in atherosclerosis 
remain controversial.
Th1 cells producing high amounts of 
interferon (IFN)-g are the most populated 
pathogenic T cells in atherosclerosis. IFN-γ 
has many detrimental effects in atherosclerosis 
including promotion of atherosclerotic lesion 
development and destabilization. IFN-g is 
reported to initiate activation of monocytes/
macrophages and DCs, resulting in the pathogenic 
Th1 response continuation.4 Interleukin (IL)-12 
produced by monocytes/macrophages also has 
crucial roles in Th1 differentiation, production of 
IFN-g, and inhibition of IL-4 and IL-5 production 
in T cells. Th1 immune responses have been 
shown to be critical in the development of many 
inflammatory diseases such as colitis, multiple 
sclerosis, diabetes, and rheumatoid arthritis.
Th2 cells release IL-4, IL-5, IL-10, and IL-
13, and afford support for antibody generation 
by B cells. IL-4 induces the expression of 
the transcription factor GATA-3 via STAT-6 
activation and stimulates Th2 cell differentiation, 
leading to up-regulation of IL-4 and IL-5 and 
inhibition of IFN-g. These responses may oppose 
pro-atherogenic Th1 immune responses yielding 
atheroprotective state. However, the significance 
of Th2 immune responses in atherosclerosis 
remains disputable.
The development of Th17 cells, which 
produce IL-17, the pro-inflammatory mediator, 
is promoted by growth factor (TGF)-β in the 
presence of IL-6 and IL-23. Several studies 
support a pro-atherogenic role for Th17 cells,5,6 
whereas some studies demonstrate a protective 
role for IL-17 in atherosclerosis.7,8 Further 
studies are needed to determine the role of this 
T cell subset in atherosclerosis development and 
progression. 
REGULATORY T CELLS PROFILE
Given that the mammalian immune system 
protects its host from invading pathogenic 
microbes and suppresses pathogenic immune 
responses, discrimination between self and non-
self seems to be important for the maintenance of 
unresponsiveness of the adaptive immune system 
to self-antigens. Sakaguchi et al first reported that 
naturally arising Tregs thymus-derived Tregs 
constitutively express high levels of CD25 (IL-2 
receptor α-chain) molecule, and that depletion 
of this population elicits autoimmunity similar 
to the human counterparts.9 Firm evidence has 
shown that Tregs expressing the transcription 
factor Foxp3, which is a master regulator of 
Treg development and function, and is currently 
the most reliable molecular marker for them, 
play a crucial role in dominant suppression of 
pathogenic immune responses, maintenance 
of self-tolerance,  and immune homeostasis.10 
Several subsets of Tregs including Foxp3+ 
Tregs, IL-10-producing T regulatory type 1 
cells, and TGF-β-producing T helper type 3 
cells can differentiate from naïve T cells in the 
periphery under certain conditions, and are called 
adaptive or induced Tregs which share similar 
immunological properties with thymus-derived 
Foxp3+ Tregs.11
Tregs have many functions in regulating 
immune balance. They play crucial roles in 
governing peripheral immune responses, 
down-regulating inflammatory reactions, 
and intercepting autoimmune disorder. Tregs 
dampen Teff immune responses through several 
mechanisms. First is through a direct contact 
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mechanism. A co-inhibitory molecule cytotoxic 
T-lymphocyte–associated antigen-4 (CTLA-4) is 
constitutively expressed by Tregs. One important 
mechanism for CTLA-4-dependent suppression 
is down-modulation of antigen-presenting cell 
function by reducing their CD80 and CD86 
expression12 or inhibition of CD80/CD86-CD28 
co-stimulatory pathways, which may lead to 
suppression of T-cell activation. Thus, Tregs 
modulate the immune response through direct 
contact with other inflammatory cells.
Next mechanism involves killing of 
inflammatory cells through production of 
serine proteases family called granzymes. 
High expression of granzyme-B has been 
shown in Tregs. Mice lacking granzyme-B 
show decreased suppressive activity of Tregs.13 
Beside granzyme-B, other factors such as tumor 
necrosis factor-related apoptosis inducing ligand 
(TRAIL)/death receptor 5 (DR5) and galectin-1 
also have been shown to be involved in inducing 
Teff apoptosis and dampening its responses by 
Tregs.14,15
The third mechanism is through the 
production of immunosuppressive cytokines such 
as transforming growth factor (TGF)-β, IL-10, 
and IL-35. TGF-β suppresses immune reactions 
via promoting Treg generation and suppressive 
function by inducing Foxp3 expression.16 
Blocking TGF-β signaling in T cells aggravates 
atherosclerosis in atherosclerosis-prone mice, 
suggesting an indispensable role of this cytokine 
in the regulation of atherosclerosis.17 IL-10 
deficiency accelerates atherosclerotic plaque 
development, associated with increased amount 
and activity of inflammatory cells and pro-
inflammatory cytokines.17 IL-35 is required for 
Treg-mediated immune suppression19 and may 
play a role in preventing atherosclerosis.20
The fourth mechanism is through metabolic 
disturbance of target cells. This mechanism is 
through IL-2, CD39, and CD73 pathways. Teffs 
apoptosis may be induced by Tregs via depleting/
consuming IL-2.21 Other metabolic disruptive 
mechanism is through the expression of CD39 
and CD73 ectoenzymes. These ectoenzymes 
hydrolyze extracellular adenosine triphosphate 
(ATP) to produce pericellular adenosine.22,23 
Adenosine A2A receptor stimulation not only 
suppresses Teff function but also promotes Tregs 
induction by decreasing IL-6 expression and up-
regulating TGF-β expression.24
Figure 1. Tregs suppress Teff via 4 mechanisms. 1) direct 
contact mechanism; 2) granzymes release; 3) suppressive 
cytokines production; and 4) metabolic interference results 
in increased adenosine.
PROTECTIVE ROLES OF TREGS IN 
ATHEROSCLEROSIS
Atherosclerosis is a chronic inflammatory 
disorder with many complex immunological 
properties interactions. Recent experimental 
evidence has indicated that Tregs inhibit 
atherosclerosis development or progression and 
induce regression of established atherosclerotic 
plaque by dampening Teff responses.25 Treg-
mediated immune suppression includes multiple 
mechanisms described before.
Several subsets of Tregs have been shown 
to play a crucial role in the suppression of 
atherosclerosis.26-29 Ait-Oufella et al.26 have 
shown that CD4+CD25+ Treg deficiency due 
to reconstitution with CD80-/-/CD86-/- or 
CD28-/- bone marrow is associated with a 
significant increase in atherosclerotic lesions 
in low-density lipoprotein receptor-deficient 
mice, indicating that endogenous CD4+CD25+ 
Tregs play a protective role in atherogenesis 
in mice.26 Although Tregs are considered to 
have constitutively high expression of CD25 
molecule,9 Teffs also express this molecule 
upon activation. The DEREG (depletion of 
regulatory T cells) mouse expressing a diphtheria 
toxin receptor under the control of the foxp3 
gene locus is a quite useful tool to analyze the 
precise role of Foxp3+ Tregs in atherosclerosis, 
because diphtheria toxin injection to this mouse 
can induce selective and efficient depletion of 
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marrow transplantation model and demonstrated 
that depletion of Foxp3+ Tregs leads to a 
substantial increase of atherosclerosis in low-
density lipoprotein receptor-deficient mice, 
which is associated to an increase in plasma 
cholesterol levels with an atherogenic lipoprotein 
profile.28 Further studies will be required to 
elucidate the precise role of Foxp3+ Tregs in the 
modulation of lipoprotein metabolism.
Therapeutic approaches such as the use 
of FcR-non-binding anti-CD3 monoclonal 
antibody,29,31 IL-2/anti-IL-2 monoclonal antibody 
complex,32 their combination,33 and active 
form of vitamin D3 have been shown to be 
effective for preventing atherosclerosis through 
induction of Tregs.34 Abdominal aortic aneurysm 
associated with atherosclerosis is prevented 
by shifting the Treg/Teff balance toward 
Tregs.35 Intravenous administration of anti-CD3 
monoclonal antibody, in addition to lowering 
plasma cholesterol, is demonstrated to induce 
rapid regression of established atherosclerosis 
in atherosclerosis-prone mice by enhancing 
a Treg-mediated immune response.36 We 
recently reported that ultraviolet B exposure 
prevents atherosclerosis by enhancing a 
regulatory immune response and suppressing 
Teff responses in hypercholesterolemic mice.37 
We also demonstrated that CTLA-4, one of 
essential molecules for Treg-mediated immune 
suppression, regulates atherosclerosis by 
suppressing pro-atherogenic immune responses 
and could be an attractive therapeutic target for 
atherosclerosis.38  Thus, therapeutic intervention 
aimed at inhibiting a Teff-mediated immune 
response or enhancing a Treg-mediated immune 
response may be a valuable approach for 
preventing atherosclerosis.
In addition to a possible protective role for 
Tregs in experimental atherosclerosis, many 
clinical studies have shown their importance in 
human atherosclerotic disease. Several recent 
studies have reported reduced peripheral Treg 
numbers in patients with acute coronary syndrome 
compared with healthy controls or patients with 
stable angina, suggesting that decreased numbers 
of Tregs may be responsible for the pathogenic 
inflammation in acute coronary syndrome.39-42 
However, only a few reports examined peripheral 
Treg levels in patients with stable coronary 
plaques. We recently reported that patients with 
coronary artery disease have reduced Treg/Teff 
ratio compared with healthy controls, suggesting 
potential importance of Tregs in human coronary 
artery disease.43 Prospective studies are required 
to ascertain whether reduced Treg levels promote 
atherosclerosis in humans.
CONCLUSION
Atherosclerosis is a chronic inflammatory 
disorder, in which Teffs responses have 
been shown to aggravate atherosclerosis. 
On the other hand, Tregs play a protective 
role against atherosclerosis. Tregs maintain 
immunological balance and regulates Teff 
immune responses through several mechanisms. 
Recent experimental evidence suggests that 
Tregs can act as a paramount factor in the 
inflammation series of atherosclerosis. Thus, 
Treg-targeted therapy could be a possible 
approach to improve cardiovascular outcome. 
However, recent experimental studies have 
shown that under inflammatory conditions such 
as atherosclerosis, Tregs become dysfunctional 
and differentiate into proinflammatory Th1-
like cells, which may contribute to promotion 
of arterial inflammation and atherosclerosis 
development.44,45 The plasticity and stability of 
Tregs remain controversial issues and additional 
studies are required. Moreover, further clinical 
studies are needed to elucidate Treg function and 
roles in human atherosclerotic disease.
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